Antifungal drug susceptibility testing

David W. Warnock; Elizabeth M. Johnson

doi:10.1097/00001432-199712000-00006

Antifungal drug susceptibility testing

David W. Warnock^*
, Elizabeth M. Johnson

^*Corresponding author for this work

Bristol Mycology Reference Laboratory General

Research output: Contribution to journal › Short survey › peer-review

1 Citation (Scopus)

Abstract

With the development of a standardized broth macrodilution reference method for in-vitro testing of Candida spp. and Cryptococcus neoformans, it is now possible to correlate antifungal drug minimum inhibitory concentrations with clinical outcome, and to establish interpretive breakpoints for different infections. More convenient methods (broth microdilution and agar diffusion) of testing are now being evaluated by comparison with the standard reference method, and modifications of this procedure also appear promising for the in-vitro testing of filamentous fungi.

Original language	English
Pages (from-to)	444-448
Number of pages	5
Journal	Current Opinion in Infectious Diseases
Volume	10
Issue number	6
DOIs	https://doi.org/10.1097/00001432-199712000-00006
Publication status	Published - 1997

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1097/00001432-199712000-00006

Cite this

@article{d5402246c10946fba6c405a79c6089f8,

title = "Antifungal drug susceptibility testing",

abstract = "With the development of a standardized broth macrodilution reference method for in-vitro testing of Candida spp. and Cryptococcus neoformans, it is now possible to correlate antifungal drug minimum inhibitory concentrations with clinical outcome, and to establish interpretive breakpoints for different infections. More convenient methods (broth microdilution and agar diffusion) of testing are now being evaluated by comparison with the standard reference method, and modifications of this procedure also appear promising for the in-vitro testing of filamentous fungi.",

author = "Warnock, \{David W.\} and Johnson, \{Elizabeth M.\}",

year = "1997",

doi = "10.1097/00001432-199712000-00006",

language = "English",

volume = "10",

pages = "444--448",

journal = "Current Opinion in Infectious Diseases",

issn = "0951-7375",

publisher = "Lippincott Williams and Wilkins",

number = "6",

}

TY - JOUR

T1 - Antifungal drug susceptibility testing

AU - Warnock, David W.

AU - Johnson, Elizabeth M.

PY - 1997

Y1 - 1997

N2 - With the development of a standardized broth macrodilution reference method for in-vitro testing of Candida spp. and Cryptococcus neoformans, it is now possible to correlate antifungal drug minimum inhibitory concentrations with clinical outcome, and to establish interpretive breakpoints for different infections. More convenient methods (broth microdilution and agar diffusion) of testing are now being evaluated by comparison with the standard reference method, and modifications of this procedure also appear promising for the in-vitro testing of filamentous fungi.

AB - With the development of a standardized broth macrodilution reference method for in-vitro testing of Candida spp. and Cryptococcus neoformans, it is now possible to correlate antifungal drug minimum inhibitory concentrations with clinical outcome, and to establish interpretive breakpoints for different infections. More convenient methods (broth microdilution and agar diffusion) of testing are now being evaluated by comparison with the standard reference method, and modifications of this procedure also appear promising for the in-vitro testing of filamentous fungi.

UR - https://www.scopus.com/pages/publications/0030729923

U2 - 10.1097/00001432-199712000-00006

DO - 10.1097/00001432-199712000-00006

M3 - Short survey

AN - SCOPUS:0030729923

SN - 0951-7375

VL - 10

SP - 444

EP - 448

JO - Current Opinion in Infectious Diseases

JF - Current Opinion in Infectious Diseases

IS - 6

ER -

Antifungal drug susceptibility testing

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this